

CITATION REPORT

List of articles citing

Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus

DOI: 10.1161/hypertensionaha.118.12060
Hypertension, 2019, 73, 84-91.

Source: <https://exaly.com/paper-pdf/74579469/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
36	Association of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 1336-1345	6.9	15
35	The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. <i>Diabetologia</i> , 2019 , 62, 1988-1997	10.3	21
34	Early Rapid Decline in Kidney Function as a Beneficial Sign After Starting Antihypertensive Medication. <i>Journal of the American Heart Association</i> , 2019 , 8, e013145	6	1
33	Kidney disease trials for the 21st century: innovations in design and conduct. <i>Nature Reviews Nephrology</i> , 2020 , 16, 173-185	14.9	8
32	Observational analyses from ADVANCE and ADVANCE-ON. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22 Suppl 2, 19-32	6.7	0
31	ACE-Triggered Hypertension Incites Stroke: Genetic, Molecular, and Therapeutic Aspects. <i>NeuroMolecular Medicine</i> , 2020 , 22, 194-209	4.6	4
30	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2925-2936	12.7	30
29	Intensive BP Control and eGFR Declines: Are These Events Due to Hemodynamic Effects and Are Changes Reversible?. <i>Current Cardiology Reports</i> , 2020 , 22, 117	4.2	2
28	The challenge of early glomerular filtration rate decline in response to antihypertensive treatment and chronic kidney disease outcomes. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	
27	Renin-Angiotensin System Blockade in Advanced Kidney Disease: Stop or Continue?. <i>Kidney Medicine</i> , 2020 , 2, 231-234	2.8	7
26	AKI-A Relevant Safety End Point?. <i>American Journal of Kidney Diseases</i> , 2020 , 75, 508-512	7.4	5
25	Initial Estimated Glomerular Filtration Rate Decline and Long-Term Renal Function During Intensive Antihypertensive Therapy: A Post Hoc Analysis of the SPRINT and ACCORD-BP Randomized Controlled Trials. <i>Hypertension</i> , 2020 , 75, 1205-1212	8.5	18
24	Characterization and implications of the initial estimated glomerular filtration rate dip upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , 2021 , 99, 750-762	9.9	33
23	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021 , 99, 999-1009	10.9	23
22	Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1420-1425	6.7	2
21	Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction. <i>Journal of Human Hypertension</i> , 2021 , 35, 499-509	2.6	3
20	eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined.. <i>Kidney360</i> , 2021 , 2, 1042-1047	1.8	8

19	The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 987-1000	2.9	6
18	Association between early worsening of kidney function and poor outcomes in patients treated with renin angiotensin system inhibitors: A meta-analysis. <i>Nephrology</i> , 2021 , 26, 772-781	2.2	
17	Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2114-2122	6.4	2
16	Rising serum potassium and creatinine concentrations after prescribing renin-angiotensin-aldosterone system blockade: how much should we worry?. <i>World Journal of Pediatrics</i> , 2021 , 17, 552-554	4.6	
15	Renin-angiotensin-aldosterone system inhibitors and major cardiovascular events and acute kidney injury in patients with coronary artery disease. <i>Pharmacotherapy</i> , 2021 ,	5.8	1
14	Angiotensin converting enzyme inhibitors in nephrology. <i>Klinicka Farmakologie A Farmacie</i> , 2020 , 33, 35-38	0.1	
13	Creatinine increase following initiation of antihypertensives is associated with cardiovascular risk: a nationwide cohort study. <i>Journal of Hypertension</i> , 2020 , 38, 2519-2526	1.9	1
12	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	0
11	The Stockholm CREATinine Measurements (SCREAM) project: Fostering improvements in chronic kidney disease care.. <i>Journal of Internal Medicine</i> , 2022 ,	10.8	1
10	Hypertension. 2022 , 511-528		
9	Sacubitril-Valsartan in Patients with Ischemic Cardiomyopathy Undergoing Off-Pump Coronary Artery Bypass Grafting-Is It Safe?. <i>Thoracic and Cardiovascular Surgeon</i> , 2022 ,	1.6	
8	KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD.. <i>American Journal of Kidney Diseases</i> , 2022 ,	7.4	1
7	11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022.. <i>Diabetes Care</i> , 2022 , 45, S175-S184	14.6	15
6	[New aspects of pharmacological nephroprotection].. <i>Der Internist</i> , 2022 , 1	0	
5	Determining Factors Influencing RAS Inhibitors Re-Initiation in ICU: A Modified Delphi Method. <i>Canadian Journal of Kidney Health and Disease</i> , 2022 , 9, 205435812211122	2.3	
4	Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> ,	4.6	0
3	Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality. 2022 , 17, 1139-1149		
2	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update. 2022 ,		8

1 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes 2023. **2023**, 46, S191-S202 ○